COO David Berger steps down Dec 31; transitions to part-time advisor through 2024

TANDEM DIABETES CARE INC

Berger resigns as EVP & COO effective Dec 31, 2023; no successor named.
Advisory period Jan–Jun 2024: part-time employee at $29,139/month plus $43,709 retention bonus.
Consulting period Jul–Dec 2024: independent contractor up to 8 hrs/month; time-based equity vesting ceases.
Prior severance agreement terminated upon separation; equity awards continue vesting during advisory period.
Berger eligible for 2023 corporate bonus; no bonus for 2024 or later.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David B. Berger

Executive Vice President and Chief Operating Officer

TNDM · TANDEM DIABETES CARE INC

Effective: 2023-12-31
Filed: December 11, 2023, 6:59 PM ET

on November 7, 2023, the Company and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that Mr. Berger will be stepping down from his current position effective December 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David B. Berger departed as Executive Vice President and Chief Operating Officer at TANDEM DIABETES CARE INC.

Action: stepping down
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

on November 7, 2023, the Company and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that Mr. Berger will be stepping down from his current position effective December 31, 2023.

View on SEC.gov

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-23-000253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.